<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817464</url>
  </required_header>
  <id_info>
    <org_study_id>TV46046-WH-10075</org_study_id>
    <nct_id>NCT02817464</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle</brief_title>
  <official_title>A Two-part, Phase 1, Exploratory and Dose-range Finding Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following a Single Subcutaneous Administration of TV-46046 in Women With Ovulatory Cycle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FHI 360</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pharmacodynamic and pharmacokinetic study is to identify a dose of&#xD;
      TV-46046 (within the range 80 to 300 mg) that is both safe and consistent with contraceptive&#xD;
      effect when injected every 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 7, 2016</start_date>
  <completion_date type="Actual">December 3, 2018</completion_date>
  <primary_completion_date type="Actual">December 3, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum progesterone concentration</measure>
    <time_frame>Baseline, Days: 1, 2, 4, 6, 8, 10, 12; then weekly through week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Medroxyprogesterone acetate (MPA) concentration</measure>
    <time_frame>Baseline, Days: 1, 2, 3, 5, 7, 10, 12, 14, 18, 20; 28, 35, 42; then at weeks 8, 10, 12, 13, 15, 17, 19, 21, 23, 25, 26, 28, 30, and 32; and then every 28 days until week 52 (in Part 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed serum drug concentration at day 182 (Cmax)</measure>
    <time_frame>Baseline, Days: 1, 2, 3, 5, 7, 10, 12, 14, 18, 20; 28, 35, 42; weeks 8, 10, 12, 13, 15, 17, 19, 21, 23, 25, 26, 28, 30, and 32; and then every 28 days until week 52.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed serum drug concentration (tmax)</measure>
    <time_frame>Baseline, Days: 1, 2, 3, 5, 7, 10, 12, 14, 18, 20; 28, 35, 42; weeks 8, 10, 12, 13, 15, 17, 19, 21, 23, 25, 26, 28, 30, and 32; and then every 28 days until week 52.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum drug concentration by time curve from time 0 to day 182 (AUC0-182)</measure>
    <time_frame>Baseline, Days: 1, 2, 3, 5, 7, 10, 12, 14, 18, 20; 28, 35, 42; weeks 8, 10, 12, 13, 15, 17, 19, 21, 23, 25, 26, 28, 30, and 32; and then every 28 days until week 52.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration time-curves (AUC0-∞)</measure>
    <time_frame>Baseline, Days: 1, 2, 3, 5, 7, 10, 12, 14, 18, 20; 28, 35, 42; weeks 8, 10, 12, 13, 15, 17, 19, 21, 23, 25, 26, 28, 30, and 32; and then every 28 days until week 52.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal half-life</measure>
    <time_frame>Baseline, Days: 1, 2, 3, 5, 7, 10, 12, 14, 18, 20; 28, 35, 42; weeks 8, 10, 12, 13, 15, 17, 19, 21, 23, 25, 26, 28, 30, and 32; and then every 28 days until week 52.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed serum drug concentration (Cmax)</measure>
    <time_frame>Day 7, week 13, 32, 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to observed serum drug concentration (tmax)</measure>
    <time_frame>Day 7, week 13, 32, 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed serum drug concentration at day 210 (C210)</measure>
    <time_frame>Day 7, week 13, 32, 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed serum drug concentration at day 182 (C182)</measure>
    <time_frame>Day 7, week 13, 32, 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum drug concentration by time curve from time 0 to day 182 (AUC0-182)</measure>
    <time_frame>Day 7, week 13, 32, 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma/serum drug concentration by time curve from time 0 to day 210 (AUC0-210)</measure>
    <time_frame>Day 7, week 13, 32, 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time-curves from time zero (AUC0-∞)</measure>
    <time_frame>Day 7, week 13, 32, 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>78 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Pregnancy</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>TV-46046 - 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TV-46046 - 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TV-46046 - 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TV-46046 - 400 mg/mL</intervention_name>
    <description>A single subcutaneous injection in the abdomen of TV-46046 - 400 mg/mL</description>
    <arm_group_label>TV-46046 - 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TV-46046 - 200 mg/mL</intervention_name>
    <description>A single subcutaneous injection in the abdomen of TV-46046 - 200 mg/mL</description>
    <arm_group_label>TV-46046 - 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TV-46046 - 300 mg/mL (if warranted)</intervention_name>
    <description>A single subcutaneous injection in the abdomen of TV-46046 - 300 mg/mL (if warranted)</description>
    <arm_group_label>TV-46046 - 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  has regular menstrual cycle (24 to 35 days)&#xD;
&#xD;
          -  is at low risk of pregnancy (ie, sterilized, in exclusively same-sex partnership, in&#xD;
             monogamous relationship with vasectomized partner, or using non-hormonal IUD)&#xD;
&#xD;
          -  is in good general health as determined by a medical history and physical examination&#xD;
&#xD;
          -  is not pregnant and does not have desire to become pregnant in the subsequent 36&#xD;
             months&#xD;
&#xD;
          -  has had a normal mammogram within the last year (for Part 1 only)&#xD;
&#xD;
               -  additional criteria apply, please contact the investigator for more information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  has hypertension:&#xD;
&#xD;
               -  systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 mm Hg&#xD;
&#xD;
               -  vascular disease&#xD;
&#xD;
          -  has current or history of ischemic heart disease&#xD;
&#xD;
          -  has history of stroke&#xD;
&#xD;
          -  has history of thromboembolic event&#xD;
&#xD;
          -  has systemic lupus erythematosus&#xD;
&#xD;
               -  positive (or unknown) antiphospholipid antibodies&#xD;
&#xD;
               -  severe thrombocytopenia&#xD;
&#xD;
          -  has rheumatoid arthritis on immunosuppressive therapy&#xD;
&#xD;
          -  has migraine with aura&#xD;
&#xD;
          -  has unexplained vaginal bleeding&#xD;
&#xD;
          -  has diabetes&#xD;
&#xD;
          -  has strong family history of breast cancer (defined as one or more first degree&#xD;
             relatives, breast cancer occurring before menopause in three or more family members,&#xD;
             regardless of degree of relationship, and any male family member with breast cancer),&#xD;
             or current or history of breast cancer, or undiagnosed mass detected by breast exam&#xD;
&#xD;
          -  has current or history of cervical cancer&#xD;
&#xD;
          -  has severe cirrhosis (decompensated) or liver tumors&#xD;
&#xD;
          -  has known significant renal disease&#xD;
&#xD;
          -  used Depo-Provera Contraceptive Injection or Depo-subcutaneous Provera 104 (DMPA)&#xD;
             products in the past 12 months&#xD;
&#xD;
          -  used any of the following medications within 1 month prior to enrollment:&#xD;
&#xD;
               -  any investigational drug&#xD;
&#xD;
               -  prohibited drugs per protocol&#xD;
&#xD;
               -  oral contraceptives, contraceptive ring or patch&#xD;
&#xD;
               -  levonorgestrel intrauterine system (LNG IUS) or contraceptive implant&#xD;
&#xD;
          -  used a combined injectable contraceptive in the past 6 months&#xD;
&#xD;
          -  less than 3 months since the end of last pregnancy&#xD;
&#xD;
          -  currently lactating&#xD;
&#xD;
          -  is using or plans to use prohibited drugs per protocol in the next 18 months&#xD;
&#xD;
          -  has known sensitivity to MPA or inactive ingredients&#xD;
&#xD;
          -  has a plan to move to another location in the next 24 months&#xD;
&#xD;
          -  in the opinion of the investigator, potentially at elevated risk of HIV infection (eg,&#xD;
             HIV -positive partner, IV drug use by self or by partner)&#xD;
&#xD;
               -  additional criteria apply, please contact the investigator for more information&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>Teva Branded Pharmaceutical Products R&amp;D, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 001</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 002</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Chile</country>
    <country>Dominican Republic</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 27, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

